U.S. Markets closed

VanEck Vectors Pharmaceutical ETF (PPH)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
54.06-0.01 (-0.02%)
At close: 3:59PM EDT
People also watch
TTHBBHHHHIAHIIH
Full screen
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Net AssetsN/A
NAVN/A
PE Ratio (TTM)N/A
YieldN/A
YTD ReturnN/A
Beta (3y)N/A
Expense Ratio (net)N/A
Inception DateN/A
Trade prices are not sourced from all markets
  • Market Realist5 days ago

    Sanofi’s Revenue Growth in 2Q17

    At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. The above chart shows Sanofi’s…

  • Market Realist6 days ago

    Pfizer’s Important Product Developments in 2Q17

    Pfizer’s (PFE) innovative health business and essential health business are focusing on growth. To strengthen the innovative health business, the company is focusing on the development of new drugs…

  • Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk
    InvestorPlace7 days ago

    Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is enjoying a phenomenal 2017, up over 110% year-to-date. Vertex Pharmaceuticals specializes in cystic fibrosis (CF) treatment. Since its early days, Vertex has grown to become the world leader in CF treatment innovations, offering multiple patient options.